Cancer – HA-1 TCR: T-Cell Immunotherapy for Treating Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant Clinical Trial
What is the goal of this study?
Researchers are testing a type of T-cell therapy for patients with acute leukemia that has come back or does not respond to treatment after a donor stem cell transplant.
This therapy uses specific T cells provided by a donor to target a protein called HA-1 that is found on leukemic cells in some patients.
This phase 1 trial will focus on finding out how much of the therapy to give, how to give it, how often to give it and when side effects occur.
Who can join the study?
This study might be a good fit for children and adults who:
- Have had their acute leukemia come back or did not respond to treatment after a donor stem cell transplant
- Express the HLA-A*0201 gene
- Have the HA-1 protein on their leukemia cells
- Have an adult stem cell transplant donor who is matched and is able to donate additional cells for this therapy
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
You can read more about the study protocol on clinicaltrials.gov.
Who can I contact for more information?
Please email the research coordinator to learn more about the study.